New drug tested for Tough-to-Treat cancers after standard therapies fail
NCT ID NCT05731947
Summary
This early-phase study tested a new oral drug called revumenib (SNDX-5613) in 42 adults with advanced colorectal cancer or other solid tumors that had worsened despite at least one prior treatment. The main goals were to find a safe dose, see how the body processes the drug, and check for early signs that it might help control tumor growth. The study was completed and results will inform whether larger trials are warranted.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
Manhattan, New York, 10065, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.